Cadrenal Therapeutics, Inc. has new directors and officers after some left, along with new pay plans for them.

Sep 29, 2026, 5:51 PM ETNew sharesRead the original at SEC EDGAR

Bad for CVKD

CVKD's stockholders approved up to 960,000 new shares from existing warrants and added 323,542 shares to the award pool. Those approvals could expand the share count, outweighing routine director and auditor votes.

CVKD · Cadrenal Therapeutics, Inc.

AI read · Bad for CVKD

The AI's read

The new permissions give the company room to issue more stock, which can leave each current owner's slice smaller. The meeting also re-elected a director and approved its auditor, but those routine votes do not balance the possible increase in shares.

Get alerts for CVKD

Follow Cadrenal Therapeutics, Inc. (CVKD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CVKD

Free on the App Store and Google Play, or on the web.